Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Buys $24,840.24 in Stock

Posted by Joseph Griffin on May 21st, 2026

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) major shareholder Ra Capital Management, L.P. acquired 996 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $24.94 per share, with a total value of $24,840.24. Following the acquisition, the insider owned 6,376,968 shares of the company’s stock, valued at approximately $159,041,581.92. This represents a 0.02% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

On Tuesday, May 19th, Ra Capital Management, L.P. acquired 3,802 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.97 per share, with a total value of $94,935.94.
On Tuesday, May 12th, Ra Capital Management, L.P. acquired 6,387 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.90 per share, with a total value of $159,036.30.
On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.81 per share, with a total value of $989,149.89.
On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.98 per share, with a total value of $37,045.34.
On Thursday, May 7th, Ra Capital Management, L.P. acquired 9,906 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.46 per share, with a total value of $242,300.76.
On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.60 per share, with a total value of $1,673,242.80.
On Tuesday, May 5th, Ra Capital Management, L.P. acquired 97,411 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.63 per share, with a total value of $2,399,232.93.
On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Stock Performance

Shares of NASDAQ COAG traded down $0.17 during midday trading on Thursday, hitting $26.30. 193,388 shares of the stock traded hands, compared to its average volume of 251,804. Hemab Therapeutics Holdings, Inc. has a one year low of $23.00 and a one year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last announced its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th.

View Our Latest Stock Report on Hemab Therapeutics

About Hemab Therapeutics

(Get Free Report)

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.